These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
356 related articles for article (PubMed ID: 31211144)
41. Seven-Day Vonoprazan-Based Triple Therapy as First-Line Helicobacter pylori Treatment in Comparison With Extended Sequential Therapy: A Randomized Controlled Trial. Chiu YT; Lee FJ; Kuo CY; Chen YT; Lin YC; Liang KS; Wu CY; Lin RT; Lin JT; Chang CY Helicobacter; 2024; 29(4):e13129. PubMed ID: 39164808 [TBL] [Abstract][Full Text] [Related]
42. Vonoprazan and amoxicillin dual therapy as the first-line treatment of Helicobacter pylori infection: A systematic review and meta-analysis. Du RC; Hu YX; Ouyang Y; Ling LX; Xu JY; Sa R; Liu XS; Hong JB; Zhu Y; Lu NH; Hu Y Helicobacter; 2024; 29(1):e13039. PubMed ID: 38036941 [TBL] [Abstract][Full Text] [Related]
43. Vonoprazan-based versus proton pump inhibitor-based therapy in Chen PY; Tsai FP; Chen MJ; Yang HY; Wu MS; Liou JM Gut; 2024 Apr; 73(5):872-874. PubMed ID: 37001979 [No Abstract] [Full Text] [Related]
44. Meta-analysis of Helicobacter pylori eradication therapy using vonoprazan as an acid suppressor compared with bismuth quadruple therapy. Yang H; Zhang M; Ma G; Yang J; Wang K; Jiang S; Dong J; Han Y Helicobacter; 2024; 29(2):e13059. PubMed ID: 38443329 [TBL] [Abstract][Full Text] [Related]
45. Vonoprazan, a novel potassium-competitive acid blocker, as a component of first-line and second-line triple therapy for Helicobacter pylori eradication: a phase III, randomised, double-blind study. Murakami K; Sakurai Y; Shiino M; Funao N; Nishimura A; Asaka M Gut; 2016 Sep; 65(9):1439-46. PubMed ID: 26935876 [TBL] [Abstract][Full Text] [Related]
46. Vonoprazan With Amoxicillin or Amoxicillin and Clarithromycin for the Treatment of Liu L; Nahata MC Ann Pharmacother; 2023 Oct; 57(10):1185-1197. PubMed ID: 36688309 [TBL] [Abstract][Full Text] [Related]
47. Dual Therapy with Vonoprazan and Amoxicillin Is as Effective as Triple Therapy with Vonoprazan, Amoxicillin and Clarithromycin for Eradication of Helicobacter pylori. Furuta T; Yamade M; Kagami T; Uotani T; Suzuki T; Higuchi T; Tani S; Hamaya Y; Iwaizumi M; Miyajima H; Umemura K; Osawa S; Sugimoto K Digestion; 2020; 101(6):743-751. PubMed ID: 31434101 [TBL] [Abstract][Full Text] [Related]
48. Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysis. Rokkas T; Gisbert JP; Malfertheiner P; Niv Y; Gasbarrini A; Leja M; Megraud F; O'Morain C; Graham DY Gastroenterology; 2021 Aug; 161(2):495-507.e4. PubMed ID: 33839101 [TBL] [Abstract][Full Text] [Related]
49. Efficacy and safety of a new rifabutin-based triple therapy with vonoprazan for refractory Helicobacter pylori infection: A prospective single-arm study. Hirata Y; Yamada A; Niikura R; Shichijo S; Hayakawa Y; Koike K Helicobacter; 2020 Oct; 25(5):e12719. PubMed ID: 32602161 [TBL] [Abstract][Full Text] [Related]
51. Vonoprazan: A Novel and Potent Alternative in the Treatment of Acid-Related Diseases. Yang X; Li Y; Sun Y; Zhang M; Guo C; Mirza IA; Li YQ Dig Dis Sci; 2018 Feb; 63(2):302-311. PubMed ID: 29282636 [TBL] [Abstract][Full Text] [Related]
52. Comparison of vonoprazan and proton pump inhibitors for eradication of Helicobacter pylori. Shinozaki S; Nomoto H; Kondo Y; Sakamoto H; Hayashi Y; Yamamoto H; Lefor AK; Osawa H Kaohsiung J Med Sci; 2016 May; 32(5):255-60. PubMed ID: 27316584 [TBL] [Abstract][Full Text] [Related]
54. Effect of CYP2C19 genetic polymorphisms on the efficacy of proton pump inhibitor-based triple therapy for Helicobacter pylori eradication: a meta-analysis. Zhao F; Wang J; Yang Y; Wang X; Shi R; Xu Z; Huang Z; Zhang G Helicobacter; 2008 Dec; 13(6):532-41. PubMed ID: 19166419 [TBL] [Abstract][Full Text] [Related]
55. Amoxicillin-vonoprazan dual therapy for Helicobacter pylori eradication: A systematic review and meta-analysis. Ouyang Y; Wang M; Xu YL; Zhu Y; Lu NH; Hu Y J Gastroenterol Hepatol; 2022 Sep; 37(9):1666-1672. PubMed ID: 35716370 [TBL] [Abstract][Full Text] [Related]